Document:

Amendment No. 1 to the 2009 Stock Plan

 Exhibit 10.72 
 AMENDMENT TO THE 
 PALM, INC. 
 2009 STOCK PLAN 
 PALM, INC. (the “Company”), having adopted the Palm, Inc. 2009 Stock Plan (the “Plan”), hereby amends the Plan, effective as of December 16, 2009, as follows: 
 1. Section 4(a)(iv) of the Plan is hereby amended and restated in its entirety to read as follows: 
 “(iv) Other Administration. Other than as provided above, the Plan shall be administered by (A) the Board or
(B) a Committee, which committee shall be constituted to satisfy Applicable Laws. Notwithstanding the foregoing or any provision in Section 4 of the Plan to the contrary, no discretionary Award granted to a Director who is not an
Employee (“Non-Employee Director”) may be granted or modified by any person other than a Committee comprised solely of Non-Employee Directors.” 
 2. Except as otherwise set forth herein, the terms of the Plan shall continue in full force and effect. 
 IN WITNESS WHEREOF, the Company, by its duly authorized officer, has executed this Amendment to the Plan effective as of December 16, 2009. 
  

			
	 PALM, INC.

		
	By:	 	/S/     DOUGLAS C.
JEFFRIES        
	Name:	 	Douglas C. Jeffries
	Title:	 	SVP and CFOFourth Agreement Regarding Private Placement of Securities

 Exhibit 10.1 
 FOURTH AGREEMENT REGARDING PRIVATE PLACEMENT OF SECURITIES 
 OF 
 SUNESIS PHARMACEUTICALS, INC. 
 THIS AGREEMENT (the “Agreement”) is made and entered into
as of this 29th day of March, 2010, by and among
SUNESIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and the persons and entities listed on Exhibit A hereto (the
“Investors”). 
 RECITALS 
 A. The Company and the Investors wish to amend that certain Investor Rights Agreement, dated April 3, 2009, as amended
June 29, 2009 and October 27, 2009 (as amended, the “Rights Agreement”), by and among the Company and the Investors (as defined in the Rights Agreement); 
 B. Pursuant to Section 8(c) of the Rights Agreement, Section 7(b) of the Rights Agreement may be amended only by written
consent of the Company, the Majority Investors (as defined in the Rights Agreement) and Alta Partners, Bay City Capital, NEA and Nextech (each as defined in the Rights Agreement); and 
 C. The undersigned hold or have the right to acquire at least a majority-in-interest of the total Unit Shares and constitute the
Majority Investors and include Alta Partners, Bay City Capital, NEA and Nextech (collectively, the “Requisite Investors”). 
 AGREEMENT 
 NOW,
THEREFORE, in consideration of these premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 1. AMENDMENT TO RIGHTS AGREEMENT. All capitalized terms not otherwise defined in this
Section 2 shall be as defined in the Rights Agreement. The Company and the undersigned hereby agree that Section 7(b)(2) of the Rights Agreement is hereby amended and restated to read as follows: 
 “Subject to Section 7(b)(6) below, from and after the earlier to occur of (i) the Second Unit Closing,
(ii) the Common Equity Closing and (iii) the closing of an Alternative Common Stock Financing in which the Investors exercise preemptive rights pursuant to the terms of this Agreement and, as a result, beneficially own greater than a
majority of the Company’s voting stock as of such closing, the Company shall take all appropriate action to promptly establish and maintain the size of the Board at nine (9) members, five (5) of which shall be Investor Designees and
nominated in accordance with the provisions of this Section 7(b). Alta Partners, Bay City Capital, NEA and Nextech, together with their respective affiliates, shall each have the right to designate one (1) such Investor Designee.
Notwithstanding the foregoing, the Company’s obligation to set and maintain the size of the Board at nine (9) members and the Investors’ right to designate five (5) Investor Designees pursuant to this Section 7(b)(2) shall
not be effective prior to May 1, 2010 or such later date as determined by the Majority Investors. On or prior to January 20 of each year in which the Majority Investors have rights pursuant to this Section 7(b) (assuming the
Company has made a request therefor at least five (5) Trading Days prior thereto), and within five (5) Trading Days of the request by the Company in connection with the preparation of a proxy statement with respect to the election of
members of the Board or a vacancy created on

  

 1. 

 
the Board by the resignation, death or disability of an Investor Designee or the failure of an Investor Designee to be elected at a meeting of the Company at any time at which the Majority
Investors have rights pursuant to this Section 7(b), each Investor shall notify the Company of the number of voting shares of the Company’s capital stock beneficially owned by such Investor as of a date within five (5) Trading Days of
the delivery of such notice.” 
 2. MISCELLANEOUS. This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same instrument. A facsimile, telecopy or other reproduction of this Agreement may be executed by one or more parties hereto and delivered by such party by
facsimile or any similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen. Such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any
party hereto, all parties hereto agree to execute and deliver an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof. Other than as set forth herein, the Rights Agreement shall remain in full force and effect.
All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of California, without regard to the principles
of conflicts of law thereof. Upon the execution of this Agreement by the Company and the Requisite Investors, all parties to the Rights Agreement shall be bound by this Agreement. 
 [SIGNATURE PAGE TO FOLLOW] 
  

 2. 

 IN WITNESS WHEREOF, the
parties hereto have executed this Agreement as of the date first above written. 
  

							
	COMPANY:	    	INVESTORS:
		
	SUNESIS PHARMACEUTICALS, INC.	    	BAY CITY CAPITAL FUND V, L.P. 
				
	Signature:	 	 /s/ Daniel N. Swisher, Jr.
	    	By:	 	 /s/ Fred Craves

				
	Print Name:	 	 Daniel N. Swisher, Jr.
	    	Name	 	 Fred Craves

				
	Title:	 	 President and CEO
	    	Title:	 	 Managing Director

				
	Address:	 	395 Oyster Point Boulevard, #400	    		 	
		 	South San Francisco, CA 94080	    		 	
		 		    	BAY CITY CAPITAL FUND V CO-INVESTMENT FUND, L.P.

				
		 		    	By:	 	 /s/ Fred Craves

				
		 		    	Name:	 	 Fred Craves

				
		 		    	Title:	 	 Managing Director

			
	GROWTH EQUITY OPPORTUNITIES FUND, LLC
		
	By:	 	 /s/ Charles W. Newton, III

		
	Name:	 	 Charles W. Newton, III

		
	Title:	 	 Manager of NEA 12 GP, LLC, which is
 the general partner of NEA Partners 12, Limited Partnership, the general partner of New Enterprise Associates 12, Limited Partnership, the sole shareholder of Growth Equity Opportunities Fund,
LLC

			
	ALTA BIOPHARMA PARTNERS III, L.P.
	
	By: Alta BioPharma Management III LLC
		
	By:	 	 /s/ Edward Hurwitz

		
	Name:	 	 Edward Hurwitz

		
	Title:	 	 Director

	
	ALTA BIOPHARMA PARTNERS III GMBH & CO. BETEILIGUNGS
KG
	
	By: Alta BioPharma Management III LLC
		
	By:	 	 /s/ Edward Hurwitz

		
	Name:	 	 Edward Hurwitz

		
	Title:	 	 Director

	
	ALTA EMBARCADERO BIOPHARMA PARTNERS III, LLC
		
	By:	 	 /s/ Edward Hurwitz

		
	Name:	 	 Edward Hurwitz

		
	Title:	 	 Manager

			
	ONC GENERAL PARTNER LIMITED AS GENERAL PARTNER OF ONC
PARTNERS, L.P.
		
	By:	 	 /s/ Michael Robinson

		
	Name:	 	 Michael Robinson

		
	Title:	 	 Director

 EXHIBIT A 
 LIST OF INVESTORS 
 Bay
City Capital Fund V, L.P. 
 Bay City Capital Fund V Co-Investment Fund, L.P. 
 Growth Equity Opportunities Fund, LLC 
 Alta BioPharma Partners III, L.P. 
 Alta BioPharma Partners III GmbH & Co. Beteiligungs KG 
 Alta Embarcadero BioPharma Partners III, LLC 
 ONC General Partner Limited as General Partner of
ONC Partners, L.P.Amended and Restated Sunesis Pharmaceuticals, Inc. 2009 Bonus Program

 Exhibit 10.2 
 SUNESIS PHARMACEUTICALS, INC. 
 AMENDED AND RESTATED
2009 BONUS PROGRAM 
 Overview 
 The 2009 Bonus Program (the “Program”) of Sunesis Pharmaceuticals, Inc. (the “Company”) was adopted effective May 8, 2009 (the “Effective Date”) and was amended
and restated on March 31, 2010. The Program is designed to motivate, retain and reward Company employees through a combination of corporate and individual performance-based incentive compensation components during the period commencing on the
Effective Date and through April 30, 2010 (the “Performance Period”), subject to the Cash Balance Threshold (as defined below). Individuals employed by the Company during the Performance Period who are designated for
participation by the Compensation Committee of the Company’s Board of Directors (the “Committee”) and who remain employed by the Company through the Payment Date (as defined below) (each a
“Participant”) shall be eligible to earn a bonus under the Program. The Program is administered by the Committee, and any decisions made in good faith by the Committee shall be final and binding on all Participants and
interested parties. 
 The Program is designed to award a cash bonus payment (each a “Cash Bonus”) for performance
during the Performance Period to Participants based in part on the level of achievement (1) by the Company of certain Company-wide objectives (the “Corporate Objectives”) and (2) by the Participant of certain
individual performance objectives, which may include certain department, group and/or team objectives applicable to such Participant (the “Individual Objectives”), subject to the Cash Balance Threshold. 
 Program Objectives 
 The Program is intended
to encourage and reward the following: 
  

	 	•	 	 the achievement of Corporate Objectives, 

	 	•	 	 the achievement of Individual Objectives, 

 as well as to recognize individual contributions and effort. 
 Determination of Program
Objectives 
 The Corporate Objectives shall be approved by the Board of Directors, with input from the Committee, management, and generally
relate to the achievement of certain research, clinical development, business development, financial, business and similar milestones. Each Corporate Objective is assigned a relative weighting from the Board of Directors, reflecting its importance
to the achievement of the Company’s key results during the Performance Period; provided, however, the Board of Directors or the Committee may adjust the weighting of the Corporate Objectives in its sole discretion at any time.

 The Individual Objectives shall be set as follows: 
  

	 	•	 	 For the Chief Executive Officer, the Individual Objectives shall be set by the Committee; 

	 	•	 	 For Participants who are executive officers (as that term is defined under Section 16 of the Securities Exchange Act of 1934, as amended, and Rule
16a-1 thereunder), other than the Chief Executive Officer (collectively, the “Executive Participants”), the Individual Objectives shall be set by the Committee based upon recommendations made by the Chief Executive
Officer; and 

	 	•	 	 For non-Executive Participants (collectively, the “Non-Executive Participants”), the Individual Objectives shall be set by each
Participant’s immediate supervisor, with input from team leaders, group and department heads and others, as appropriate. 

 Cash Balance Threshold 
 Notwithstanding the foregoing, in the event the Company’s cash balance does not equal or exceed at
least $25 million on or before July 31, 2010 (such funds to be derived solely from the proceeds of one or more transactions that, in the Committee’s sole discretion, are deemed to be aligned with the value-creating objectives of the
Program), no Cash Bonuses will be earned under the Program irrespective of whether or not the Corporate Objectives and/or Individual Objectives are otherwise deemed achieved by the Participants (the “Cash Balance Threshold”).

 Program Bonus Targets 
 Under
the Program, each Participant is eligible to earn a cash bonus in an amount up to a specified percentage of his or her annual base salary that is earned in 2009, with such percentage based in part upon the position such Participant holds with the
Company (the “Bonus Target”). Under the Program, the Bonus Targets range from 25% to 40% of a Participant’s 2009 base salary for Vice President level employees and above and from 6% to 20% of a Participant’s 2009
base salary for other Participants. 
 Determination of Cash Bonus Payments 
 The Company will determine the achievement of Corporate Objectives and Individual Objectives shortly after the end of the Performance Period, as follows: 
 Determination of Level of Achievement of Corporate Objectives 
 The Committee shall determine, after receiving and considering analysis and recommendations from management, the degree to which the Corporate Objectives have been met, expressed as a percentage of
Corporate Objectives achieved, taking into consideration the weighting assigned to each Corporate Objective. Based on the percentage of Corporate Objectives achieved, the Committee will then determine the final aggregate bonus pool under the Program
for all Participants (the “Bonus Pool”). 
 Adjustment of Bonus Targets based on Level of Achievement of Corporate
Objectives 
 Bonus Target levels for Participants will be adjusted based on level of achievement of Corporate Objectives as
determined by the Committee. For example, if the Committee determines that only 80% of the Program’s Corporate Objectives are achieved, each Participant’s Bonus Target will be decreased by 20% (in other words, a Participant with a 10%
Bonus Target will have that Bonus Target reduced to 8%, or 80% of 10%.) Such adjusted Bonus Targets are referred to as the “Adjusted Bonus Targets.” 
 Determination of Bonus Payments for Individual Participants 
 Subject to the Company’s cash balance exceeding the Cash Balance Threshold, the actual Cash Bonus earned by a Participant is based on the Participant’s (i) level of contribution to the
achievement of the Corporate Objectives; (ii) level of achievement by the Participant against his or her Individual Objectives and (iii) Adjusted Bonus Target (or, if the Bonus Target was not adjusted, the original Bonus Target). There is
no set formula for determining the amount of Cash Bonus earned based on the achievement of Individual Objectives or Corporate Objectives. Rather, the Committee shall exercise its discretion in

  

 2. 

 
determining the amount of Cash Bonus actually earned, which determination will be final and binding. In making its determination, the Committee shall consider the following: 
  

	 	•	 	 For the Chief Executive Officer, the Committee’s own evaluation of his achievements; 

	 	•	 	 For Executive Participants, the recommendations made by the Chief Executive Officer; and 

	 	•	 	 For Non-Executive Participants, the recommendations made by members of the Executive Committee with input from team leaders, group and department heads
and supervisors, as appropriate. 

 In determining the actual Cash Bonus earned, the Committee may also take into account the
achievement of publicly announced targets, clinical milestones, strategic goals, cross-functional teamwork and collaboration, and unforeseen changes in the economy and/or geopolitical climate. 
 Timing of Cash Payments Under the Program 
 Payment of Cash Bonuses under the Program is expected to occur upon the later of (a) the first quarter following the conclusion of the Performance Period or (b) within fifteen (15) business after the Company’s cash
balance exceeds the Cash Balance Threshold, on such date as determined by the Committee in its sole discretion (the “Payment Date”). A Participant must remain employed by the Company through the Payment Date in order to earn
any Cash Bonus. In no event will the Payment Date occur after March 15, 2011, as the Program is intended to comply with Treasury Regulation Section 1.409A-1(b)(4) and will be interpreted and administered in compliance therewith to the
greatest extent possible. 
 Miscellaneous Provisions 
 Participation in the Program shall not alter in any way the at will nature of the Company’s employment of a Participant, and such employment may be terminated at any time for any reason, with or
without cause and with or without prior notice. Nothing in this Program shall be construed to be a guarantee that any Participant will receive all or part of a Cash Bonus or to imply a contract between the Company and any Participant.
 This Program supersedes and replaces all prior cash incentive and bonus plans of the Company, other than the Change of Control Payment Plan and severance
plans (both Executive and Non-Executive). The Committee may amend or terminate this Program at any time, with or without notice. The Committee may likewise terminate an individual’s participation in the Program at any time, with or without
notice. Further, the Board of Directors or Committee may modify the Corporate Objectives, the Individual Objectives, the Bonus Targets and/or the weighting of the Corporate Objectives at any time. 
 The Program shall be interpreted in accordance with California law without reference to conflicts of law principles. 
  

 3.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]